Article Versions Notes

Millán M, DeGregorio-Rocasolano N, Pérez de la Ossa N, Reverté S, Costa J, Giner P, Silva Y, Sobrino T, Rodríguez-Yáñez M, Nombela F, et al. Targeting Pro-Oxidant Iron with Deferoxamine as a Treatment for Ischemic Stroke: Safety and Optimal Dose Selection in a Randomized Clinical Trial. Antioxidants. 2021; 10(8):1270. https://doi.org/10.3390/antiox10081270

Millán, Mònica, Núria DeGregorio-Rocasolano, Natàlia Pérez de la Ossa, Sílvia Reverté, Joan Costa, Pilar Giner, Yolanda Silva, Tomás Sobrino, Manuel Rodríguez-Yáñez, Florentino Nombela, and et al. 2021. "Targeting Pro-Oxidant Iron with Deferoxamine as a Treatment for Ischemic Stroke: Safety and Optimal Dose Selection in a Randomized Clinical Trial" Antioxidants 10, no. 8: 1270. https://doi.org/10.3390/antiox10081270

Millán, M., DeGregorio-Rocasolano, N., Pérez de la Ossa, N., Reverté, S., Costa, J., Giner, P., Silva, Y., Sobrino, T., Rodríguez-Yáñez, M., Nombela, F., Campos, F., Serena, J., Vivancos, J., Martí-Sistac, O., Cortés, J., Dávalos, A., & Gasull, T. (2021). Targeting Pro-Oxidant Iron with Deferoxamine as a Treatment for Ischemic Stroke: Safety and Optimal Dose Selection in a Randomized Clinical Trial. Antioxidants, 10(8), 1270. https://doi.org/10.3390/antiox10081270